Your Messages Inbox
Most Viewed Abstracts
1. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 2. Omega-3 fatty acids for bipolar disorder 3. Is folic acid good for everyone 4. ACS Releases Guidelines for HPV Vaccination 5. Vitamin D - A review Free full text
Your Article Summary
See Latest ArticlesAtherosclerosis profile and incidence of cardiovascular events: a population-based survey
BMC Cardiovascular Disorders, 09/22/09
Robinson JG et al. – Self–report of subclinical atherosclerosis identified an extremely high–risk group with a >25% risk of a CVD event in the next 2 years. These characteristics may be useful for identifying individuals for more aggressive diagnostic and therapeutic efforts.
Related Articles
Variant metabolic risk factor profile leading to premature coronary disease: time to define the syndrome of accelerated atherocoronary metabolic syndrome in Asian Indians
Singapore Medical Journal, 11/11/09
Relevance Score: 93%
Enhanced neutrophil expression of annexin-1 in coronary artery disease
Metabolism-Clinical and Experimental, 10/26/09
Relevance Score: 93%
Relationship of heavy drinking, lipoprotein (a) and lipid profile to infrarenal aortic diameter
Vascular Medicine, 10/13/09
Relevance Score: 92%
Analysis of breast cancer related gene expression using natural splines and the Cox proportional hazard model to identify prognostic associations
Breast Cancer Research and Treatment, 11/09/09
Relevance Score: 90%
BTNL2 gene polymorphisms may be associated with susceptibility to Kawasaki disease and formation of coronary artery lesions in Taiwanese children
European Journal of Pediatrics, 11/05/09
Relevance Score: 89%
Today in Atherosclerosis/Lipids...keeping you current
Receive free subspecialty "5-minute updates" via email
Cardiovascular and Economic Outcomes After Initiation of Lipid-Lowering Therapy With Atorvastatin vs Simvastatin in an Employed Population
Mayo Clinic Proceedings, 12/11/09
Subclinical Atherosclerosis In Young beta-thalassemia Major Patients
Hemoglobin, 12/11/09
Year Two Assessment of Fenofibric Acid and Moderate-Dose Statin Combination: A Phase 3, Open-Label, Extension Study
Clinical Drug Investigation, 12/11/09
Sponsor
Article Search
Sponsor
Sponsor